SQ
SQZB.US SQZ Biotechnologies Company
- Market cap
- USD 708K
- P/E
- -
- P/B
- 0.44x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is SQZB.US undervalued?
Graham numberThe Graham number of SQZ Biotechnologies Company cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SQZ Biotechnologies Company fundamental analysis
No fundamental analysis for SQZ Biotechnologies Company yet.
SQZ Biotechnologies Company stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck,…
Full company profileSQZ Biotechnologies Company financial statements
SQZ Biotechnologies Company annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 12.7M | 20.1M | 21.0M | 27.1M | 21.0M | 12.2M |
| Gross Profit | 12.7M | 20.1M | 21.0M | 16.1M | 9.79M | - |
| Operating Income | -20.4M | -34.3M | -51.1M | -68.8M | -80.7M | -60.8M |
| EBITDA | -18.2M | -29.9M | -40.1M | -57.7M | -64.1M | - |
| Net Income | -20.2M | -32.2M | -50.5M | -68.7M | -79.5M | -71.6M |
| EPS | -0.82 | -1.31 | -2.04 | -2.49 | -2.76 | - |
| Balance Sheet | ||||||
| Total Assets | 116M | 152M | 231M | 226M | 107M | - |
| Total Liabilities | 52.7M | 93.8M | 104M | 102M | 50.0M | - |
| Shareholders' Equity | 62.9M | 58.6M | 127M | 124M | 57.1M | - |
| Cash & Short-term Investments | 107M | 98.3M | 170M | 144M | 63.7M | - |
| Total Debt | - | 42.3M | 47.1M | 69.7M | 34.4M | - |
| Cash Flow | ||||||
| Operating Cash Flow | 21.1M | -33.5M | -43.2M | -82.1M | -83.5M | -74.3M |
| Capital Expenditure | 1.31M | 2.17M | 1.18M | 613K | 522K | 213K |
| Free Cash Flow | 19.8M | -35.7M | -44.3M | -82.8M | -84.1M | -74.5M |
| Ratios | ||||||
| ROE | -32.2% | -55.0% | -39.7% | -55.4% | -139.0% | - |
| ROA | -17.5% | -21.1% | -21.9% | -30.4% | -74.1% | - |
| Net Profit Margin | -159.7% | -160.1% | -240.6% | -253.7% | -377.9% | -587.4% |
| Debt to Equity | - | 0.72x | 0.37x | 0.56x | 0.60x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
SQZ Biotechnologies Company dividends
SQZ Biotechnologies Company has not paid dividends in the last 6 fiscal years.
Last stock split: 1:10 on Jul 7, 2023.
Who owns SQZ Biotechnologies Company
- Insiders 0.00%
- Institutions 0.02%
- Public & others 99.98%
- Shares outstanding 29.5M
- Free float 26.1M
SQZ Biotechnologies Company company profile
- Company name
- SQZ Biotechnologies Company
- Ticker
- SQZB.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 53
- Fiscal year end
- December
- Address
- 200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472
- Phone
- 617 758 8672
- Website
- sqzbiotech.com
About SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
SQZ Biotechnologies Company management
4- Mr. Lawrence J. Knopf Esq.General Counsel & Secretary · born 1962
- Dr. Marshelle Smith Warren M.D.Chief Medical Officer · born 1963
- Dr. Robert S. Langer Jr., Ph.D., ScDCo-Founder & Member of Scientific Advisory Board · born 1949
- Ms. Ipsita Roymoulik Ph.D.Senior Vice President of CMC & QUALITY